SCHEMBL3479929

SCHEMBL3479929

N#Cc1ccccc1N1CCN(S(=O)(=O)c2ccc(CNC(=O)c3ccc(Cl)cc3)s2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.60
DRD4 P21917 7/20 0.60
DRD3 P35462 7/20 0.60
MAPK9 P45984 1/20 0.56
MAPK10 P53779 1/20 0.56
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
BCL2 P10415 1/20 0.48
BCL2L1 Q07817 1/20 0.48
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7440295 0.91 DRD2 (0.54) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL4197405 0.89 DRD2 (0.48) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL2423962 0.88 MAPK9 (0.58) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL27657550 0.87 MAPK9 (0.57) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL2423386 0.87 MAPT (0.60) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL2418948 0.86 MAPK9 (0.59) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL27479114 0.86 MAPK9 (0.56) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL2424858 0.85 MAPK9 (0.61) DRD2DRD4MAPK9MAPK10MEN1
SCHEMBL3479867 0.85 KMT2A (0.61) DRD2DRD4DRD3MAPK9MAPK10
SCHEMBL2421336 0.84 MAPK9 (0.55) DRD2DRD4DRD3MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US claimed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 US claimed
EP-1663193-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES Applied Research Systems ARS Holding N.V. (AN) 2006-06-07 EP claimed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 EP claimed
WO-2005025558-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2005-03-24 WO claimed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN claimed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN claimed
EP-1218374-A1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2002-07-03 EP claimed
WO-2001023378-A1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-05 WO claimed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 EP claimed
US-8658640-B2 JNK inhibitors for the treatment of endometriosis MERCK SERONO SA (CH) 2014-02-25 US disclosed
US-8592414-B2 JNK inhibitors for the treatment of endometriosis Merck Serono, S.A. (CH) 2013-11-26 US disclosed
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-24 US disclosed
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-10 US disclosed
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US disclosed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 EP disclosed
WO-2005097116-A1 COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-10-20 WO disclosed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN disclosed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN disclosed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS DRD2 2094/4885DRD4 1625/4885DRD3 1208/4885
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN DRD2 3926/4885DRD4 4209/4885DRD3 3658/4885
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN DRD2 3926/4885DRD4 4209/4885DRD3 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.